GH - Guardant Health, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
85.21
-2.31 (-2.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close87.52
Open86.66
Bid85.11 x 800
Ask85.17 x 1400
Day's range85.01 - 87.25
52-week range55.90 - 112.22
Volume406,076
Avg. volume1,066,807
Market cap8.427B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.83
Earnings date04 Aug 2020 - 10 Aug 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est110.00
  • Here's Why Guardant Health Dropped 10.2% in June
    Motley Fool

    Here's Why Guardant Health Dropped 10.2% in June

    A public offering of common stock pushed the stock lower, but strengthened the company's balance sheet.

  • Buying These 3 Stocks Could Make You Crazy Rich
    Motley Fool

    Buying These 3 Stocks Could Make You Crazy Rich

    Many simply don't have sufficient growth opportunities. Here are three growth stocks you can buy right now that could make you crazy rich over the long run. Alteryx (NYSE: AYX) provides a solution for this all-too-common scenario.

  • Buying These 3 Stocks Is a Brilliant Move to Make Right Now
    Motley Fool

    Buying These 3 Stocks Is a Brilliant Move to Make Right Now

    Alteryx currently claims only a sliver of that ginormous market. Customers love how easy Alteryx's software makes analyzing large amounts of data. It's not surprising that Alteryx now has more than 6,400 customers across every major industry, including 37% of the Global 2000.

  • Could Guardant Health Be a Millionaire-Maker Stock?
    Motley Fool

    Could Guardant Health Be a Millionaire-Maker Stock?

    It has been less than two years since Guardant Health's (NASDAQ: GH) IPO in October 2018. Since that time, shares of the cancer diagnostic company have returned 298%, compared to the S&P 500's 2.47% return during the same period. A modest investment of $10,000 in Guardant Health's IPO would have grown to $39,863 today.

  • Investing $5,000 in These 3 Stocks Could Make You a Fortune Over the Next 10 Years
    Motley Fool

    Investing $5,000 in These 3 Stocks Could Make You a Fortune Over the Next 10 Years

    There are a few fantastic growth stocks that you can buy right now that have a good shot at making you a lot of money relatively quickly. David Gardner, co-founder of The Motley Fool, thinks that investors should "make your portfolio reflect your best vision for our future." One really positive vision for the future is a world where most cases of cancer can be detected early enough to be successfully treated.

  • Guardant Health Inc (GH) Q1 2020 Earnings Call Transcript
    Motley Fool

    Guardant Health Inc (GH) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q1 2020 Earnings Call. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2020.

  • Will Guardant Health Continue to Surge Higher?
    Zacks

    Will Guardant Health Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Guardant Health

  • Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify
    Zacks

    Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

    Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

  • 5 Top-Ranked Stocks to Tap Earnings Beat Potential
    Zacks

    5 Top-Ranked Stocks to Tap Earnings Beat Potential

    Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.

  • Have $1,000? Consider Investing It in 1 of These Hot Growth Stocks
    Motley Fool

    Have $1,000? Consider Investing It in 1 of These Hot Growth Stocks

    Consider investing it in one of these hot growth stocks and holding your position for at least five years. Alteryx (NYSE: AYX) solves this problem. Users love Alteryx's software so much that it won the 2019 Gartner Peer Insights Customers' Choice award for data science and machine learning platforms.

  • Guardant Health, Inc. Just Reported, And Analysts Assigned A US$113 Price Target
    Simply Wall St.

    Guardant Health, Inc. Just Reported, And Analysts Assigned A US$113 Price Target

    It's been a mediocre week for Guardant Health, Inc. (NASDAQ:GH) shareholders, with the stock dropping 13% to US$75.79...

  • Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
    Zacks

    Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

    Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

  • Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4
    Zacks

    Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

    Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

  • Guardant Health (GH) Dips More Than Broader Markets: What You Should Know
    Zacks

    Guardant Health (GH) Dips More Than Broader Markets: What You Should Know

    Guardant Health (GH) closed the most recent trading day at $81.80, moving -1.21% from the previous trading session.

  • SoftBank Founder Son Says He’s Open to Working With Elliott
    Bloomberg

    SoftBank Founder Son Says He’s Open to Working With Elliott

    (Bloomberg) -- SoftBank Group Corp. founder Masayoshi Son opened the door to making at least some of the changes championed by activist investor Paul Singer, after the Japanese company reported a second quarter of losses from its startup investing.Son called Singer’s Elliott Management Corp. an “important partner” and said he is in broad agreement with the investor about SoftBank buybacks and share value. Son said he is on the side of shareholders, especially since he is the largest stockholder at the company. The two billionaires held discussions a couple weeks ago, he said.Son is adopting a more conciliatory stance just as he’s stumbling with his signature effort -- the $100 billion Vision Fund, which made him the biggest investor in technology. The fund lost money in the three months ended in December, one quarter after the meltdown at WeWork triggered a record loss for the Japanese company. On Wednesday, Son said he is no longer targeting $108 billion for a second fund and SoftBank may finance the effort on its own.“We are thankful that such a distinguished investor has joined us as a friend,” Son said at a press conference in Tokyo to discuss earnings. “We are basically in agreement on carrying out large buybacks when the finances allow it.”Elliott disclosed a stake of almost $3 billion in SoftBank this month, arguing the company’s shares are substantially undervalued compared with its assets. It has advocated for a share buyback of as much as $20 billion, along with governance changes and more transparency about its investments.The Vision Fund lost 225.1 billion yen ($2.05 billion) for the three months ended in December. SoftBank Group reported a slim operating profit of 2.6 billion yen, compared with the 344.7 billion yen average of analyst estimates.The past 12 months have been a roller coaster for Son and SoftBank investors alike. A year ago, the company unveiled a record buyback, sparking a rally that pushed shares to the highest since its dot-com peak in 2000. Uber Technologies Inc.’s disappointing public debut and the implosion of WeWork wiped out the gains over the next few months. But SoftBank surged again in the past week after Singer disclosed his stake and Son won approval to sell his Sprint Corp. to T-Mobile US Inc.SoftBank shares are up about 21% this year. They were little changed in Tokyo trading Thursday.Son focused on the positive in the presentation to shareholders and the media in Tokyo. He said the Vision Fund is on track to return to profit in the current quarter. The eight portfolio companies that are publicly trading, including Uber, Slack Technologies Inc. and Guardant Health Inc., have added $3 billion in paper profit in the current three months, he said.“At the last earnings briefing I used the words ‘I regret’ 20 times. But after a difficult winter always comes spring,” Son said. “The tide is turning,” he added, standing in front of a slide with the same words and a crashing wave.The most dramatic change in portfolio value since the quarter closed was Uber, whose shares have climbed more than 35% this year. That, Son said, means the Vision Fund’s stake is now worth $1.5 billion more than its investment, compared with $1 billion less at the end of December.The Vision Fund’s overall performance was murkier. SoftBank said the fund’s portfolio remained unchanged from the previous quarter at 88 investments. It reported a gain in valuation for 29 companies in the December quarter, while 31 saw their worth decline. The unrealized gain on the investments, or the difference between the cost at which it acquired the stakes and their present fair value, shrunk to $5.2 billion. That’s less than a third of the paper profit SoftBank reported six months ago.Atul Goyal, an analyst at Jefferies Group, pointed out that the losses at Vision Fund essentially wiped out profits created by the rest of the company.“These results validate our concerns that most other things that SBG does outside of Alibaba have led to distractions or value destruction,” he wrote in a research note.Vision Fund 2 Is Risk to SoftBank Investors, Analyst Says (Video)SoftBank said it is introducing new governance standards for its portfolio companies, including the composition of the board of directors, founder and management rights, rights of shareholders, and mitigation of potential conflicts of interest. The new rules will “enhance value creation and liquidity” at portfolio companies, it said in a statement.Elliott wants SoftBank to set up a special committee to review the investment process at the Vision Fund, which it thinks has dragged on the share price despite making up a small portion of assets under management, people familiar with the matter have said.Son’s best bet to date is still the investment he made in Alibaba two decades ago. In the latest quarter, SoftBank said it booked a 331.9 billion yen gain from the e-commerce giant’s listing in Hong Kong.That deal turned Son’s $20 million into a stake worth over $130 billion, a spectacular return that cemented his reputation as an investor and helped him raise the original $100 billion Vision Fund. But the track record since then has been spotty. In addition to the WeWork fiasco, he suffered setbacks at portfolio companies, including Wag Labs, Zume Pizza and Brandless Inc.Son, asked repeatedly about the second Vision Fund at the conference in Tokyo, said he still wants to raise the money but acknowledged the WeWork troubles have set back those plans. Major backers of the first fund, Saudi Arabia’s Public Investment Fund and Abu Dhabi’s Mubadala Investment Co., have remained on the sidelines so far. He said SoftBank may start with a smaller, bridge fund so it can keep doing deals.“A lot of our planned investors have been worried by the trouble at WeWork and Uber and we heard their feedback,” Son said. “It’s fully possible for us to carry on investing entirely with our own funds.”He wasn’t precise about what the size of the fund would be, and said that it “seems right that the scale is somewhat reduced this time.”At a Milken Institute conference in Abu Dhabi on Wednesday, Vision Fund head Rajeev Misra said that the second fund has already made seven investments and another six are in the pipeline. About a dozen companies from the first fund are expected to list in the next 18 months, he said.“There’s no rush, they don’t need capital,” Misra said. “A lot of them won’t even raise capital through an IPO, it will be a direct listing.”SoftBank has weighed contributing $40 billion to $50 billion for the second fund, people familiar with the matter have said.“The company will struggle to fund both Vision Fund II and buybacks unless they get a large outside commitment to VF II,” Chris Lane, an analyst with Sanford C. Bernstein, said prior to the announcement.SoftBank’s last share re-purchase was announced about a year ago, a record 600 billion yen.The company’s own sum-of-parts calculation puts its total value at more than 12,000 yen a share. That’s more than double SoftBank’s actual share price, which values the company at about $110 billion. Elliott thinks SoftBank’s net asset value could be about $230 billion, people familiar with the discussions have said.Son urged investors to focus on SoftBank’s shareholder value, which would include its stake in Alibaba, rather than operating profit, which is swayed by share price fluctuation in investments like Uber. To illustrate, he showed a slide with a famous visual illusion that can look like a duck or a rabbit depending on perspective.“The only measure by which SoftBank, an investment company, should be evaluated by is whether shareholder value rises or falls,” he said.(Updates with shares in eighth paragraph)\--With assistance from Nicolas Parasie.To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Takahiko Hyuga in Tokyo at thyuga@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at echan273@bloomberg.net, Peter ElstromFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
    Zacks

    Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

    Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

  • Should Growth Investors Buy this Cancer Screening Biotech Stock?
    Zacks

    Should Growth Investors Buy this Cancer Screening Biotech Stock?

    Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

  • Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

    Is (GH) Outperforming Other Medical Stocks This Year?

  • Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks

    Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.

  • Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
    Zacks

    Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

    Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

  • Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Guardant Health (GH) closed at $80.59, marking a +0.93% move from the previous day.

  • Did Business Growth Power Guardant Health's (NASDAQ:GH) Share Price Gain of 114%?
    Simply Wall St.

    Did Business Growth Power Guardant Health's (NASDAQ:GH) Share Price Gain of 114%?

    Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...

  • Jazz Enrolls First Patient in Phase II/III Leukemia Study
    Zacks

    Jazz Enrolls First Patient in Phase II/III Leukemia Study

    Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

  • Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
    Zacks

    Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease

    Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.

  • BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
    Zacks

    BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

    BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more